Skip to main content

Clinical trial RESGEX

Randomized, controlled, open-label, multicenter, phase II study to evaluate the efficacy and safety of CetuGEXTM plus chemotherapy in comparison to cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neck

Cancers
Organ Multiple
Trial status Trial closed
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor Glycotope
EudraCT Identifier 2013-003695-13
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02052960
Inclusion criteria EGFR+
Last update